Oncology Clinicians’ Attitudes on Hormonal Therapy After Chemoradiotherapy for Cervical Cancer
Menée aux Etats-Unis à partir d'une enquête auprès de 209 cliniciens, cette étude examine leur attitude concernant la prescription d'un traitement hormonal après une chimioradiothérapie pour un cancer du col de l'utérus
Introduction : Premenopausal patients with locally advanced cervical cancer (LACC) treated with chemoradiotherapy often experience iatrogenic menopause due to ovarian ablation from radiotherapy.1 Hormonal therapy (HT) safely and effectively treats menopausal symptoms after pelvic radiotherapy.2,3 Despite clinical practice guidelines recommending HT, it remains underused.1,4 This survey study assesses gynecologic oncology (GYO) and radiation oncology (RO) clinician attitudes, HT prescribing patterns, and barriers to prescribing HT after chemoradiotherapy for cervical cancer.
Methods : For this survey study, we administered a questionnaire about HT for patients with LACC after chemoradiotherapy, following American Association for Public Opinion Research (AAPOR) reporting guidelines, to GYO and RO physicians and advanced practice professionals from April 23 to June 9, 2025. Participants were recruited through the listservs of Society of Gynecologic Oncology (SGO), the American Brachytherapy Society (ABS), and experts in cervical cancer brachytherapy. The survey collected demographic characteristics, cervical cancer practice patterns, and instances of prescribing HT. Race and ethnicity were self-reported. The study was approved by the University of Kentucky institutional review board, and participants provided written informed consent. Statistics were calculated using IBM SPSS, version 30 (IBM Corp), using the
χ2 and Fisher exact tests, with analyses conducted by specialty to assess practice differences. All P values were from 2-sided tests and results were deemed statistically significant at P
< .05.
Results : Of 209 participants who started the survey (9.4% of 1490 eligible SGO and 0.3% of 10 000 ABS), 186 (89.0%) completed it and 178 (95.7%) were eligible (Table 1). Participants included members of SGO (75.3% [n = 140]), ABS (16.7% [n = 31]), and gynecologic RO experts (3.8% [n = 7]). Most were attending physicians (GYO, 77.9% [106 of 136]; RO, 81.0% [34 of 42]) and women (GYO, 76.5% [104 of 136]; RO, 59.5% [25 of 42]) and see 1 to 5 patients with cervical cancer per month (GYO, 58.8% [80 of 136]; RO, 57.1% [24 of 42]). Most of the participants always discuss iatrogenic menopause with patients before chemoradiotherapy (GYO, 62.5% [85 of 136]; RO, 78.6% [33 of 42]).
JAMA Network Open , article en libre accès, 2026